{"product_id":"a-vrio-analysis","title":"Agilent Technologies, Inc. (A): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eThis ready-made VRIO Analysis gives you a research-based breakdown of Agilent Technologies, Inc. Business across its \u003cstrong\u003e2026\u003c\/strong\u003e core capabilities, including instruments, CrossLab services, software, diagnostics, and capital discipline. You’ll learn how its trusted brand, recurring service revenue, LC, GC, and LC\/MS portfolio, compliance expertise for \u003cstrong\u003e21 CFR Part 11\u003c\/strong\u003e and \u003cstrong\u003eAnnex 11\u003c\/strong\u003e, and Life Sciences and Diagnostics focus create sustained and temporary competitive advantages under CEO Padraig McDonnell.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Trusted brand and installed customer base\u003c\/h2\u003e\n\u003ch3\u003eTrusted brand and installed customer base\u003c\/h3\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactor\u003c\/td\u003e\n\u003ctd\u003eReal-life data\u003c\/td\u003e\n\u003ctd\u003eVRIO effect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports global service and customer retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating groups\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTargets analytical, biopharma, and diagnostics demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e110\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWidens the installed base and brand reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounded\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1999\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong operating history supports trust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eValue: repeat purchases, premium pricing, and lower acquisition cost across \u003cstrong\u003e3\u003c\/strong\u003e major customer groups.\u003c\/li\u003e\n\u003cli\u003eRarity: global trust in scientific instruments across \u003cstrong\u003e110\u003c\/strong\u003e countries is uncommon.\u003c\/li\u003e\n\u003cli\u003eImitability: decades of validation and switching costs are difficult to copy quickly.\u003c\/li\u003e\n\u003cli\u003eOrganization: market-focused groups and service teams are built to monetize the installed base.\u003c\/li\u003e\n\u003cli\u003eCompetitive Advantage: sustained.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Agilent CrossLab service network and recurring revenue\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e FY2024 revenue base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003e1 of 3\u003c\/strong\u003e operating segments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003e3\u003c\/strong\u003e operating segments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e CrossLab is embedded in the segment structure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e1 of 3\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO item\u003c\/td\u003e\n\u003ctd\u003eReal-life data\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment count\u003c\/td\u003e\n\u003ctd\u003eOperating segments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrossLab position\u003c\/td\u003e\n\u003ctd\u003eAgilent operating segment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 of 3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: LC, GC, and LC\/MS instrument portfolio\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e3\u003c\/strong\u003e core platforms: LC, GC, and LC\/MS; fiscal 2024 revenue: \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eVRIO use\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore platforms\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLC, GC, LC\/MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCommercial scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e3\u003c\/strong\u003e major analytical platforms in one portfolio.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eLC\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGC\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLC\/MS\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e2024\u003c\/strong\u003e scale and application depth are harder to copy quickly.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e fiscal 2024 revenue supports sales and service execution.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Software, automation, and AI-enabled workflow IP\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e in fiscal 2024 revenue gives Agilent the scale to fund software, automation, and AI-enabled workflow IP. The strategic point is the link between execution software, instruments, and lab data.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAgilent’s workflow IP matters because it can improve lab efficiency, data quality, compliance, and margins while raising switching costs. The relevant scale reference is \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e in fiscal 2024 revenue.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eIntegrated execution software, automation, and cloud-native lab workflow tools are uncommon in the analytical instruments market.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIndividual features can be copied, but full platform integration with instruments and an installed base is harder to duplicate.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eOpenLab Sync, GC Assist, and enterprise AI focus show alignment between product development and commercial execution.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO test\u003c\/th\u003e\n\u003cth\u003eAgilent data\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/td\u003e\n\u003ctd\u003eCapacity to fund workflow software and automation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eOpenLab Sync, GC Assist, enterprise AI focus\u003c\/td\u003e\n\u003ctd\u003eMore differentiated than stand-alone software features\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eInstalled-base integration\u003c\/td\u003e\n\u003ctd\u003eHarder to copy than isolated tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eCross-product execution\u003c\/td\u003e\n\u003ctd\u003eSupports capture of value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/li\u003e\n\u003cli\u003eOpenLab Sync\u003c\/li\u003e\n\u003cli\u003eGC Assist\u003c\/li\u003e\n\u003cli\u003eCloud-native lab workflow tools\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Regulatory and compliance expertise\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e21 CFR Part 11\u003c\/strong\u003e and \u003cstrong\u003eAnnex 11\u003c\/strong\u003e support adoption in regulated workflows, and Agilent reported \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e in fiscal 2024 net revenue.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eRegulatory-ready workflows help customers meet \u003cstrong\u003e21 CFR Part 11\u003c\/strong\u003e and \u003cstrong\u003eAnnex 11\u003c\/strong\u003e requirements faster.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eDeep compliance knowledge combined with analytical workflows is uncommon in the same vendor stack.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eKnow-how can be copied, but validated solutions and regulatory credibility take time to build.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eLegal, product, and quality functions support execution in regulated markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO factor\u003c\/th\u003e\n\u003cth\u003eReal-life number(s)\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eAgilent Technologies, Inc. link\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21 CFR Part 11\u003c\/strong\u003e; \u003cstrong\u003eAnnex 11\u003c\/strong\u003e; \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eSupports adoption in regulated workflows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e named regulated-workflow standards\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eCompliance depth plus analytics is not widespread\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major regulatory frameworks\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eValidation and credibility take time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eFiscal \u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eScale supports regulated-market execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eValidated compliance support is hard to replace\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e21 CFR Part 11\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAnnex 11\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e fiscal 2024 net revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Biopharma and clinical diagnostics application expertise\u003c\/h2\u003e\n\n\u003cp\u003eAgilent Technologies, Inc. has a sustained advantage here because it combines biopharma, pathology, immunohistochemistry, and sequencing application support with years of workflow-specific capability building.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThis expertise supports access to pathology, immunohistochemistry, biopharma, and sequencing workflows that matter in clinical and research buying decisions.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eCross-domain depth across analytical chemistry, pathology, and clinical workflows is still uncommon.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors can enter adjacent markets, but they cannot copy customer relationships and application depth quickly.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eAgilent Technologies, Inc. has built this capability through its \u003cstrong\u003e2019\u003c\/strong\u003e BioTek acquisition for \u003cstrong\u003e$1.165 billion\u003c\/strong\u003e and its \u003cstrong\u003e3\u003c\/strong\u003e operating-group structure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO factor\u003c\/td\u003e\n\u003ctd\u003eReal-life data\u003c\/td\u003e\n\u003ctd\u003eEffect\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eBiopharma, pathology, immunohistochemistry, sequencing\u003c\/td\u003e\n\u003ctd\u003eAccess to higher-growth workflows\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eAnalytical chemistry, pathology, clinical workflows\u003c\/td\u003e\n\u003ctd\u003eFew companies cover all three well\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2019\u003c\/strong\u003e, \u003cstrong\u003e$1.165 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLonger to build than to buy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operating groups\u003c\/td\u003e\n\u003ctd\u003eCapability is structurally supported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eApplication depth is hard to replicate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2019\u003c\/strong\u003e BioTek acquisition: \u003cstrong\u003e$1.165 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operating groups\u003c\/li\u003e\n\u003cli\u003ePathology, immunohistochemistry, biopharma, sequencing\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Market-focused leadership and organizational structure\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAgilent Technologies, Inc. uses \u003cstrong\u003e3\u003c\/strong\u003e customer-facing groups: Life Sciences and Diagnostics Markets, Applied Markets, and CrossLab. FY2024 revenue was \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e. Padraig McDonnell became CEO on \u003cstrong\u003eMay 1, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA dedicated life-science operating model with \u003cstrong\u003e3\u003c\/strong\u003e named market groups is moderately uncommon in laboratory tools and diagnostics.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe structure is easy to copy. The harder part is the leadership cadence, decision speed, and culture behind it.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO factor\u003c\/td\u003e\n\u003ctd\u003eReal-life fact\u003c\/td\u003e\n\u003ctd\u003eCompetitive read\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operating groups; FY2024 revenue \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eImproves accountability, speed, and customer focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLife Sciences and Diagnostics Markets; Applied Markets; CrossLab\u003c\/td\u003e\n\u003ctd\u003eModerately uncommon structure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003ePadraig McDonnell became CEO on \u003cstrong\u003eMay 1, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHarder to copy the leadership execution than the org chart\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e-group model under the new CEO\u003c\/td\u003e\n\u003ctd\u003eSupports execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003ePadraig McDonnell and the \u003cstrong\u003e3\u003c\/strong\u003e-group structure support execution across Life Sciences and Diagnostics Markets, Applied Markets, and CrossLab.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operating groups\u003c\/li\u003e\n\u003cli\u003eCEO start date: \u003cstrong\u003eMay 1, 2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue: \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Global supply chain and manufacturing optimization\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e FY2024 revenue; \u003cstrong\u003e3\u003c\/strong\u003e reporting segments; about \u003cstrong\u003e18,000\u003c\/strong\u003e employees; fiscal year-end \u003cstrong\u003eOctober 31, 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e supports product flow, pricing power, and margin protection.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e3\u003c\/strong\u003e segments and a global supply chain are valuable, but not unique.\u003c\/p\u003e\n\n\u003ch3\u003eInimitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e25\u003c\/strong\u003e years since \u003cstrong\u003e1999\u003c\/strong\u003e do not make the network impossible to copy.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eAbout \u003cstrong\u003e18,000\u003c\/strong\u003e employees support supply-chain optimization and pricing actions.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO test\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReporting segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYears since \u003cstrong\u003e1999\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eNot durable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e FY2024 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e18,000\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e reporting segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOctober 31, 2024\u003c\/strong\u003e fiscal year-end\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAgilent Technologies, Inc. - VRIO Analysis: Financial strength and capital allocation discipline\n\u003c\/h2\u003e\n\u003cp\u003eAgilent Technologies, Inc. showed FY2024 revenue of \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e and a quarterly dividend of \u003cstrong\u003e$0.248\u003c\/strong\u003e per share, or \u003cstrong\u003e$0.992\u003c\/strong\u003e annualized. That supports R\u0026amp;D, dividends, M\u0026amp;A, and share returns, but the edge is \u003cstrong\u003etemporary\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO test\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunds R\u0026amp;D, dividends, M\u0026amp;A, and share returns\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLow\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrong balance-sheet discipline is not unique among large-cap peers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHigh\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRivals can strengthen finances over time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.248\u003c\/strong\u003e quarterly dividend; \u003cstrong\u003e$0.992\u003c\/strong\u003e annualized\u003c\/td\u003e\n\u003ctd\u003eShows disciplined deployment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial strength can be copied\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eFY2024 revenue of \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e and an annualized dividend of \u003cstrong\u003e$0.992\u003c\/strong\u003e per share show usable cash generation.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eLow\u003c\/strong\u003e; balance-sheet discipline is common among large-cap peers.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHigh\u003c\/strong\u003e; rivals can improve leverage and cash generation over time.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly dividend: \u003cstrong\u003e$0.248\u003c\/strong\u003e per share\u003c\/li\u003e\n\u003cli\u003eAnnualized dividend rate: \u003cstrong\u003e$0.992\u003c\/strong\u003e per share\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue: \u003cstrong\u003e$6.51 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516103155861,"sku":"a-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/a-vrio-analysis.png?v=1740142696","url":"https:\/\/dcf-model.com\/fr\/products\/a-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}